Metopirone (Metyrapone)

Metyrapone inhibits the adrenal enzyme 11β‑hydroxylase, blocking the final step of cortisol synthesis. This reduces cortisol levels while allowing precursor steroids to accumulate, which can be measured for diagnostic purposes or used therapeutically.

The specific dose of Metopirone is determined by the prescribing clinician based on the indication, patient characteristics, and laboratory monitoring. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for Metyrapone in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Metopirone, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metopirone is a steroidogenesis inhibitor that directly reduces cortisol synthesis, whereas other options such as ketoconazole, osilodrostat, or pituitary surgery target different steps or sources of excess cortisol. Choice of therapy depends on disease severity, comorbidities, and patient tolerance.

Metopirone should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, and avoid exposure to direct sunlight or extreme heat.

Metopirone is administered orally. The tablet (or other oral formulation) is taken with water, and the exact timing and frequency are set by the prescribing clinician based on therapeutic goals and monitoring results.

Serious risks include adrenal crisis, severe hypotension, and allergic reactions such as anaphylaxis. Patients should be monitored for signs of acute adrenal insufficiency and instructed to seek immediate medical attention if severe symptoms develop.

Metopirone is contraindicated in patients with known hypersensitivity to Metyrapone or any excipients, and it should be used with caution in individuals with severe hepatic impairment, uncontrolled hypertension, or active adrenal insufficiency without appropriate monitoring.